Interestingly, CADD522 inhibited tumorsphere formation of luminal BC cells expressing ectopic RUNX2 [16], supporting the therapeutic potential of CADD522 as an anticancer drug for BC therapy. The gene discussed is RUNX2; the disease is breast cancer.